Oncotelic Therapeutics Publishes Peer-Reviewed Validation of Deciparticle Platform, Paving Way for Improved Drug Delivery
Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with Sapu Nano, has announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle nanoparticle platform. The research details the development of Sapu003, an investigational intravenous everolimus formulation currently in a Phase 1b clinical trial, and underscores the platform's potential to transform delivery of hydrophobic therapeutic compounds.
The publication, available online, provides comprehensive data on the Deciparticle platform's formulation design, scalable cGMP manufacturing process, product stability, and preclinical performance. According to the company, these findings demonstrate the platform's ability to enable intravenous administration of drugs that are typically poorly water-soluble, a common challenge in pharmaceutical development. The study also suggests broader applications for Deciparticle beyond everolimus, including other hydrophobic drug candidates, potentially expanding its utility across multiple therapeutic areas.
Sapu003 is being evaluated in a Phase 1b dose-escalation study involving patients with advanced mTOR-sensitive solid tumors. The trial aims to assess the safety, pharmacokinetics, and preliminary antitumor activity of Sapu003 in combination with exemestane. This ongoing clinical investigation highlights the platform's real-world potential to address high unmet needs in oncology.
The implications of this validation are significant. For Oncotelic, the Deciparticle platform represents a strategic asset that could enhance its drug pipeline and partnership opportunities. For the broader biopharmaceutical industry, the platform offers a solution to the long-standing problem of delivering hydrophobic drugs, which often require complex formulations or are limited to oral administration with variable bioavailability. Intravenous delivery could improve drug exposure and efficacy, particularly in cancer therapy where precise dosing is critical.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, targeting high-unmet-need cancers and rare pediatric indications. The company also leverages its CEO Dr. Vuong Trieu's extensive patent portfolio, with over 500 patent applications and 75 issued U.S. patents. Beyond internal programs, Oncotelic engages in licensing and co-development through joint ventures, such as its 45% ownership of GMP Bio. Additionally, the company develops PDAOAI, a proprietary AI platform for drug discovery and manufacturing, which is integrated with its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP facility.
For investors and industry observers, this publication provides independent validation of a key technology that could drive future growth. The full press release is available at https://ibn.fm/gECtl. More information about Oncotelic can be found at www.oncotelic.com.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Oncotelic Therapeutics Publishes Peer-Reviewed Validation of Deciparticle Platform, Paving Way for Improved Drug Delivery.